1. A Message From Our CEO  
2. Snapshot  
3. Responsible Business Practices  
4. Commitment to Patients  
5. Employees and Culture  
6. Environmental Sustainability  
7. Frameworks and Standards
A Message From Our CEO

To Our Stakeholders:

We recently shared our 2027 Blueprint, a five-year growth strategy to achieve Precision at Scale, dramatically expanding our global patient impact by doubling our commercial portfolio and R&D productivity. With a strong foundation of enterprise capabilities, appropriate infrastructure, and a track record of success, we have confidence we can achieve our five-year plan. We are on our way toward realizing our vision of making hope for a better and longer life a reality for many more patients around the world.
Corporate responsibility is a guiding principle for how we are executing on our strategy. We are proud of who we are, what we stand for, and how we operate. In all that we do, we strive to be good corporate citizens by living our core values and effectively managing environmental, social, and governance (ESG) issues to maximize our company’s impact.

Within these pages, we present our second annual Corporate Responsibility Report, which highlights the progress we’ve made toward evolving our corporate governance as we grow as a company and continue to focus on making a positive impact on patients, communities, and our employees, and protecting the planet by reducing our environmental footprint. The development of this report was a team effort coordinated by a cross-functional Corporate Responsibility Working Group, with oversight from our Executive Team and the Nominating and Corporate Governance Committee of our Board of Directors.

Highlights from our new report include:

- Last year, AYVAKIT® (avapritinib) became the standard of care for advanced systemic mastocytosis in the U.S., with a doubling of AYVAKIT net product revenues year-over-year. As we have achieved strong patient access to commercial therapy, we have provided robust support to U.S. patients who have inadequate or no insurance coverage, with approximately 30% of medication provided for free to eligible patients in 2022.

- As our company continued to grow, we refreshed our Board with the appointment of two new independent Board members, Habib Dable and Dr. John Tsai, and evolved several components of our governance practices. Updates included approval of an overboarding policy, adoption of an average tenure goal of 10 years or less for our independent directors, and implementation of shareholder proxy access provisions in our bylaws.

- Our commitment to human capital management best practices continues to bear fruit. Recently, we were recognized as a Top Place to Work in Massachusetts by the Boston Globe and received the Top Workplaces USA award from Energage. In addition, we were ranked third for executive gender diversity and ninth for board gender diversity among the 75 largest companies in Massachusetts in a study recently published by the Eos Foundation.

- Recognizing that environmental stewardship is everyone’s responsibility, we are making a concerted effort to understand and capture metrics that are reflective of our impact on the environment. We are focusing our efforts this year by releasing an Environmental Statement to formally guide how we operate, and we anticipate providing additional updates in the future as we continue this work.

We continue to recognize that making good on our commitment to corporate responsibility is a journey, not a destination. This report represents our sustained effort to obtain and act on stakeholder feedback, show progress on performance metrics, and enhance our ESG disclosures. I am incredibly proud of our Blueprint employees, who are motivated every day by our shared mission to change the outcomes and extend the lives of patients and whose commitment to maintain a culture of transparency, trust, and integrity fuels our ability to optimize outcomes for all of our stakeholders. Nevertheless, we know there is still much work to do, and we look forward to hearing from and working with all our stakeholders to realize our vision for making a positive impact on the world around us.

Warm regards,

Kate Haviland
President, Chief Executive Officer, and Director
Blueprint Medicines
Snapshot

Blueprint Medicines Corporation (Blueprint) (Nasdaq: BPMC) is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders.

Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate our scientific innovation into a broad pipeline of important approved and investigational precision therapies aimed at addressing difficult-to-treat cancers and blood disorders.
2 approved medicines

5 breakthrough therapy designations granted by the U.S. FDA

80% success rate from IND to clinical proof of concept

4 years from IND to first approval

615 employees in the United States and Europe

$111M AYVAKIT net revenues in 2022

$477M in research and development investment in 2022

Partnerships with CSTone Pharmaceuticals, Zai Lab, Ipsen, and Proteovant Therapeutics
In 2020, our first precision therapy, AYVAKIT, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumor (GIST) harboring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations. Subsequently, AYVAKIT was approved by the FDA in 2021 for the treatment of adults with advanced systemic mastocytosis (SM), including patients with aggressive SM, SM with associated hematologic neoplasm, and mast cell leukemia.

Also in 2020, GAVRETO® was FDA approved for the treatment of adults with RET fusion-positive non-small cell lung cancer (NSCLC), adults and pediatric patients with RET-mutant medullary thyroid cancer (MTC), and adults and pediatric patients with advanced RET fusion-positive thyroid cancer who require systemic therapy and are radioactive iodine-refractory.

Today we are delivering our approved medicines to patients in the United States and Europe, and in other geographies through our partners. In addition, we are globally advancing multiple programs for mast cell disorders, lung cancer, breast cancer, and other diseases.

In 2022, we ended the year with approximately 500 patients in the U.S. on AYVAKIT treatment and net product revenues of approximately $111M. With the ongoing launch of AYVAKIT, we have successfully built out the commercial infrastructure and capabilities to deliver AYVAKIT and future life-changing medicines to patients in need. As we look forward to a potential label expansion for AYVAKIT for patients with indolent systemic mastocytosis (ISM), we are proud to say we are in a strong position to deliver the first disease-modifying therapy to patients with ISM upon approval.

Our mission:

We are working to make real the promise of precision therapy to improve and extend life for as many people with cancer and blood disorders as possible.

Our core values:

Since our founding, our Core Values have remained at the heart of how we work and are the roots of our cultural beliefs. We strive to uphold our core values every day, and we recognize and celebrate these ideals together in many ways throughout the year.

PATIENTS FIRST
We maintain intense focus on improving patients’ lives.

THOUGHTFULNESS
We explore creative approaches, daring to make well-thought-out decisions and owning the outcomes.

URGENCY
We solve complex problems rapidly, with attention and care.

TRUST
We collaborate to build and maintain a cohesive team that leads with integrity as well as mutual respect of lived experiences, viewpoints, and diverse talents.

OPTIMISM
We pursue transformative therapies that we believe will make a difference.
Our Approach to Corporate Responsibility

**OUR STRATEGY**

Our objective is to responsibly manage our business to create a sustainable company that will continue to deliver long-term value. We believe the environmental, social, and governance (ESG) strategy and priorities that we have outlined in this report are instrumental to Blueprint’s future success.

<table>
<thead>
<tr>
<th>Commitment to Patients</th>
<th>Responsible Business Practices</th>
<th>Employees and Culture</th>
<th>Environmental Sustainability</th>
</tr>
</thead>
<tbody>
<tr>
<td>We work with urgency to reach our goal of delivering safe medicines that improve patients’ lives.</td>
<td>We carry a responsibility to act ethically, lead with integrity, and uphold a sound governance framework, building long-term value and trust with stakeholders.</td>
<td>We are intentional in how we build and nurture our culture to create transparency, inclusivity, and equity. We prioritize employee development and growth, while protecting our teams’ health and well-being.</td>
<td>We are committed to understanding key environmental performance metrics and advancing environmental practices that reduce the impact of our operations.</td>
</tr>
</tbody>
</table>

Juanita S., living with lung cancer
OVERSIGHT

While the entire Board engages in corporate ESG matters, the Nominating and Corporate Governance Committee (NCGC), per its charter, has oversight of ESG-related initiatives and policies. In early 2023, our Board designated oversight of human capital management, including recruiting, retention, career development, and equity, diversity, and inclusion, to the Compensation Committee.

At the management level, our ESG Steering Committee, is composed of a subset of the Executive Team, guides overall ESG strategy and priorities. The Corporate Responsibility Working Group, which manages day-to-day operations under the direction of the Steering Committee, comprises cross-functional leaders, including representatives from clinical development, market access, human resources, legal, compliance, finance, information technology, facilities, technical operations, investor relations, and corporate affairs. Working Group responsibilities include compiling and reviewing reporting and key performance indicators across multiple domains and updating the Nominating and Corporate Governance Committee on corporate responsibility initiatives.

STAKEHOLDER ENGAGEMENT

We believe that engaging with both our internal and external stakeholders is important to our success. We learn from their perspectives and have applied these insights to inform our priorities and to accelerate progress on our ESG initiatives. We proactively engage with our stakeholders in continuous, collaborative, and transparent dialogue as outlined below.

<table>
<thead>
<tr>
<th>Stakeholders</th>
<th>Ways we engage</th>
<th>Key ESG topics addressed</th>
</tr>
</thead>
</table>
| Patients and Healthcare Professionals | • Clinical trials  
• Patient education and support  
• Travel support system  
• Patient advocacy and assistance | • Drug quality and safety  
• Access and affordability of medicines  
• Diversity and representation in clinical trials |
| Employees | • Annual engagement and enablement survey  
• Career development, training, and learning  
• Total Rewards program  
• Employee community groups driving culture initiatives | • Compensation and benefits  
• Employee engagement and retention  
• Training and development  
• Equity, diversity, and inclusion  
• Health and well-being  
• Employee health and safety |
| Investors | • Quarterly earnings calls  
• Email, calls, and in-person meetings  
• Conferences and industry forums  
• Annual shareholders’ meeting  
• Engagement with ESG stewardship teams | • Financial sustainability  
• Board composition and governance  
• Human capital management, including executive and director compensation  
• Environmental strategy  
• Equity, diversity, and inclusion approach |
| Community Partners | • Community partnerships and volunteerism  
• Philanthropic donations | • Charitable giving to support local community needs |
| Government Agencies | • Industry trade association memberships  
• Comments on proposed regulations | • Healthcare regulations and policy issues  
• Patient advocacy  
• Privacy considerations and patents |
2022 Highlights

• Strengthened our ethical business practices with an extensive assessment and update of our Code of Business Conduct and Ethics

• Refreshed our Board of Directors with the addition of Habib Dable in 2022 and Dr. John Tsai in 2023, who have extensive experience in strategic leadership and commercial growth

• Implemented an overboarding policy effective in April 2023, limiting our directors to service on a total of four public company boards (including our Board), or a total of three public company boards (including our Board) for directors who are sitting public company CEOs

• Held our second Integrity Day and launched the Integrity Champion Award

• Launched a Bias Interrupter program to increase equity in performance review cycle

As of year-end 2022:

• Globally, approximately 56% of our employees are women

• In the U.S., approximately 36% are racially/ethnically diverse

• 50% of our Executive Team members are women

• 50% of the directors on our Board are diverse by gender or race/ethnicity

• Approximately 1,200 patients worldwide have received commercial AYVAKIT since launch

About This Report

Blueprint's report covers our progress related to our ESG initiatives and strategy. Unless otherwise noted, all quantitative company data provided throughout this report covers our fiscal year 2022 (FY2022), reflecting data for the period from January 1 through December 31, 2022. We have also included certain initiatives that occurred after the end of FY2022, which we have noted as such. Throughout the report, we guide readers to additional sources of information on our corporate website for convenience.
Responsible Business Practices

Under the leadership of our Board of Directors (Board) and Executive Team, we are committed to good governance as an essential business practice and component of our corporate responsibility efforts. We apply high ethical, compliance, and legal standards across our operations.

Corporate Governance and Board Composition

At Blueprint, we are committed to strong corporate governance as we scale our impact and bring transformative precision medicines to patients globally. Over the past year, we have made important progress in strengthening our Board composition and overall governance framework. Notably, we added two independent directors who each bring extensive expertise in strategic leadership, commercial growth, and organizational scale across global pharmaceutical and emerging biotechnology companies, and extensive experience bringing innovative therapies to market across geographies and therapeutic areas. All committees are composed solely of independent directors. Overall, 80% of our directors are independent, including our designated Lead Independent Director.

Our Board believes that good governance practices are important to ensure that our company is managed for the long-term benefit of shareholders and has updated Corporate Governance Guidelines to assist in the exercise of the Board's duties and oversight responsibilities. Additional detail on director expertise can be found in our proxy statement, available on the Investor section of our website.

BOARD DIVERSITY

We believe that the effectiveness of our Board is largely a function of having highly qualified, experienced, and diverse directors focused on driving Blueprint's long-term success. Our Board members each bring distinct scientific, clinical, financial, and business backgrounds to their roles, providing diverse experiences and perspectives to their oversight of the Company. In addition, we are proud to have achieved a strong diversity profile, with 50% of our directors being diverse by gender or race/ethnicity as of January 2023.
Business Ethics and Integrity

Integrity is fundamental to everything we do at Blueprint. Our comprehensive global Compliance Program and Code of Business Conduct and Ethics set the standards for how we conduct business, and they apply to all employees, contractors, Board directors, and executive officers.

We hold an annual Integrity Day and grant an Integrity Champion Award to further foster a culture in which every employee is accountable to act with courage, feels empowered to use their voice to speak up, and does the right thing. In 2022, we featured a robust dialogue between a panel of cross-functional leaders at all levels of the organization as well as breakout discussions to further probe what it means to act with integrity.

OVERSIGHT

Blueprint’s Chief Compliance Officer has overall responsibility for the Compliance Program, with direct access to our Chief Executive Officer, and provides annual reports to the Board. We have also appointed a global Compliance Committee, consisting of senior cross-functional leadership from compliance, legal, medical affairs, finance, commercial, international, clinical, human resources, and patient advocacy, which provides management oversight of our program.

COMPLIANCE PROGRAM

Our Compliance Program is based on the seven elements of an effective program as outlined in the Compliance Program Guidance for Pharmaceutical Manufacturers issued in 2003 by the Office of the Inspector General of the U.S. Department of Health and Human Services. Blueprint has adopted the Pharmaceutical Research and Manufacturers of America (PhRMA) Code and has implemented policies and procedures that are consistent with its requirements. We periodically assess the program internally and completed an external assessment of the program in 2022 to ensure we continue to effectively meet evolving compliance needs as well as additional laws and guidance.

Education and training are essential to communicate our standards and expectations. All U.S. and global employees including part-time and certain contractors, are trained on compliance policies and guidelines that are applicable to their job functions.

CODE OF BUSINESS CONDUCT AND ETHICS

Blueprint’s Code is an extension of our mission. It articulates how we live by our core values and guides us in making ethical and legal decisions in the day-to-day of our work.

In 2022, we refreshed the Code to better articulate our commitment to integrity, and we launched an initiative to make employee aware of the updates. We require all new hires to attest to reviewing the Code and will expand required training sessions on the new Code to the full employee base in 2023. In addition, we provide training to employees in Europe that integrates elements of the European Federation of Pharmaceutical Industries and Associations Code to address region-specific considerations.

Incident Reporting

We seek to maintain an "open door" environment in which every employee is comfortable speaking up and raising questions about conduct they know or suspect may be inappropriate, without fear of retaliation. The BlueCares hotline, hosted by an independent third party and accessible globally, enables employees to raise concerns (anonymously if they choose) and is available 24 hours a day, 365 days a year. Employees are provided information regarding the hotline during new hire training, as part of our ongoing compliance training, and information is accessible via our intranet. Incident reports are reviewed by the Chief Compliance Officer, and the Chair of the Board’s Audit Committee receives direct alerts on all incidents reported through the hotline.

Code of Business Conduct and Ethics

In 2022, we refreshed the Code to better articulate our commitment to integrity, and we launched an initiative to make employees aware of the updates.
We hold an annual Integrity Day to further foster a culture in which every employee feels empowered to use their voice and act with courage.
Ethical Marketing

Customers depend on us for accurate and balanced information about the efficacy and safety of our products. We help healthcare professionals (HCPs) and patients make informed decisions by educating them about our products honestly.

RESPONSIBLE MARKETING PRINCIPLES

- We promote, market, and educate truthfully and based on accurate and well-balanced scientific information.
- We provide fair balance when discussing our products and never overstate the efficacy or downplay the risks of our products.
- We ensure that promotional communications regarding our products are consistent with the approved labels.
- We never promote our products for unapproved uses.
- We respect the clinical judgments and decisions of healthcare providers.
- We discuss products with patients and caregivers only if we are trained to do so.
Promotional materials must meet the requirements of applicable local laws, regulations, and industry codes, including the PhRMA Code on Interactions with Healthcare Professionals.

Our Promotional and Non-Promotional Medical Interactions policies guide our responses to questions on products prior to approval. To help ensure activities are carried out appropriately, field employees who engage in promotional interactions with customers receive training, consistent with their role, covering applicable laws, regulations, and industry codes. Certain contractors are also provided training to the extent that their role requires it.

In addition, we launched a U.S. Field Manual in 2021 to provide a comprehensive guidance resource on compliance policies to support our U.S. field personnel. The manual covers key laws and principles, conflicts of interest, promotional interactions, non-promotional and medical interactions, interactions with patients and patient advocacy groups, and adverse event and product complaint reporting.

Learn more by visiting the Responsible Marketing section on page 19 of Blueprint’s Code.

**GOVERNMENT RELATIONS AND PUBLIC POLICY**

Blueprint primarily engages in public policy through industry trade association memberships, including the Biotechnology Innovation Organization. We do not maintain a political action committee and did not make any contributions to political parties or candidates in 2022. In addition, we do not incentivize employees for making political contributions, and we do not engage in lobbying activities.

**Data Privacy and Security**

We recognize the importance of protecting the privacy of personal information and other confidential information. Our employees are dedicated and proficient, acting as data stewards across various areas, expertise, and professions, to protect the personal data of patients, caregivers, and the healthcare professionals who support them.

**DATA PRIVACY**

The Audit Committee of our Board of Directors receives updates regarding information security matters. The Data Privacy Taskforce, a cross-functional team including legal, compliance, information security, commercial, quality, and international legal representatives oversees data processing activities and adherence to global privacy regulations, such as General Data Protection Regulation (GDPR) and California Consumer Privacy Act (CCPA).

Our Privacy Incident Investigation and Management standard operating procedure (SOP) outlines the process for responding to potential data breach incidents. In addition, we have established a Privacy Policy, which is publicly available on our website.

Employees are required to participate in annual data privacy training, and we follow a defined data security protocol focusing on ensuring data safety and transparency in agreement with international laws and regulations governing data protection and privacy. In 2022, about 97% of employees globally completed privacy training.

**INFORMATION SECURITY**

Blueprint concentrates on securing, testing, and optimizing our technology ecosystem to protect the integrity of our data and the data of patients. Our Information Security Policy, security controls, and operating procedures are aligned with the National Institute of Standards and Technology (NIST) cybersecurity framework.

We proactively initiate monthly cybersecurity assessments and network vulnerability scans in addition to monitoring threats in real time. In 2022 and early 2023, we conducted internal and external penetration testing.

All employees are subject to periodic phishing awareness campaigns in addition to annual information security training, covering a broad range of topics such as social engineering, phishing, mobile security, and best practices to secure sensitive information.

**Risk Management and Business Continuity**

We conduct an annual Enterprise Risk Assessment that covers risk areas across the organization. The assessment results are reviewed by the Executive Team and discussed with the Audit Committee to determine appropriate mitigation strategies.

Our IT Department maintains a Disaster Recovery and Business Continuity Policy and a Disaster Recovery SOP that we test annually. During the testing, we activate standby infrastructure to ensure critical business systems will continue to operate if we are unable to operate from the Cambridge office.
Commitment to Patients

Bringing treatments to patients safely and effectively is at the core of our mission at Blueprint. From the beginning stages of research through delivering medicine into the hands of patients, we are committed to excellence.

Research and Development

Twelve years after we began operations, Blueprint has grown into one of the leading independent precision therapy companies in the world. Our founding scientists envisioned a new generation of highly selective precision therapies able to achieve potent target inhibition to enable rapid, deep, and durable responses. We have delivered on this vision — Blueprint has achieved approval of two homegrown medicines within 10 years, and we have a broad portfolio of clinical-stage precision therapies plus multiple undisclosed research programs focused on core therapeutic areas in cancer and blood disorders and expanding to include allergy.
We are continuing to invest in groundbreaking scientific research, building on our track record of research and development (R&D) success, to bring the promise of precision therapy to additional patient populations and their families. Last year, we announced the 2027 Blueprint for Precision at Scale, a five-year growth strategy to double our commercial portfolio and R&D productivity.

Beyond our R&D efforts, we have built the infrastructure and capabilities to bring these therapies to patients globally and we are now in a position to leverage this strong foundation to impact many more patients and continue to grow our commercial business.

We know that successful R&D requires collaboration and trust, especially with patients, families, and healthcare providers who participate in clinical research, and we are dedicated to advancing patient safety, transparency, and equity in all our R&D efforts.

**RESEARCH TRANSPARENCY**

We recognize the importance of disclosing research, including clinical trial results, to ensure patients, healthcare providers, scientists, and other stakeholders are able to access information and data that can inform patient care and future research. We routinely share data from our preclinical and clinical studies with the scientific community through peer-reviewed publications in medical journals and presentations at conferences, as well as provide open access to key presentations and publications on our website for all stakeholders. In 2022, we published 101 conference abstracts and 11 manuscripts, presentations, and publications, including publications in *Nature Medicine*, *Oncology, Leukemia*, and the *Journal of Medicinal Chemistry*. In addition, we register our clinical trials on ClinicalTrials.gov, EudraCT, and other relevant registry websites.

**Safety of Clinical Trials**

Across our clinical development programs, we follow review and approval procedures required by laws and regulations before initiating clinical research studies and throughout their conduct. Clinical trials are conducted by qualified Contract Research Organizations and overseen by qualified study managers in our clinical operations department who meet or exceed minimum prior experience requirements and are trained on our procedures. We protect patient safety and well-being through informed consent and routine safety monitoring and reporting, including use of independent Data and Safety Monitoring Boards, consistent with established Good Clinical Practice guidelines and other country-specific standards.

We maintain standard operating procedures to initiate recovery of distributed investigational medicinal products if there are patient or customer complaints, adverse event reports encountered during clinical studies, investigations for product quality-related issues, or mandatory decisions by regulatory authorities.
DIVERSITY IN CLINICAL TRIALS

Enrolling patients with diverse backgrounds in clinical trials is critical to evaluating the potential of new medicines across populations with unique characteristics. As part of our efforts to increase diversity in our clinical trials, we provide translation of study materials, such as informed consent forms, and partner with patient advocacy groups to expand trial awareness and participation across diverse patient populations. Trial awareness materials are reviewed by patients and include patient imagery and messaging that resonates with diverse populations.

To further expand our efforts to ensure all patients can benefit from our medical innovation, we assembled a Clinical Trial Diversity Task Force under the Chief Medical Officer to strategize additional opportunities to increase diversity and representation in trial design and execution. In 2023, to progress our efforts, we will:

- Continue to explore virtual and remote study visits to reduce potential trial burden
- Engage in proactive site selection and training to enable trial recruitment and retention of diverse patients
- Further evaluate the epidemiology of target disease areas by gender or race/ethnicity
- With a partner dedicated to dismantling barriers contributing to healthcare disparities, map Blueprint’s current clinical trial process and identify gaps preventing representative enrollment

Access to Medicines

PATIENT ACCESS

To achieve the impact we aim to make, patients must be able to broadly access our innovation. From the moment we demonstrated clinical proof-of-concept with our first precision therapy, we have considered patient access thoughtfully and with urgency. These efforts have included initiating global pre-approval access programs for our investigational therapies and designing a robust U.S. patient support program to assist patients in accessing our commercially available medicines.

"At Blueprint, we are committed to helping patients access our therapies, from removing financial barriers with our YourBlueprint® patient support program to addressing urgent medical needs with appropriate early access pathways."

— CHRISTY ROSSI, CHIEF OPERATING OFFICER
PRICING PRINCIPLES

Our pricing approach is designed to reflect our treatments’ significant benefits in rare patient populations, our commitment to patient access, and sustainable research and development of innovative precision therapies. We are committed to reinvesting product revenues into research to bring even more treatment advances to patients with cancer and blood disorders, and we price our medicines to enable our goals of sustaining patient access and our long-term R&D efforts.

EARLY ACCESS PROGRAMS FOR INVESTIGATIONAL THERAPIES

We appreciate the urgency of patients and families facing a serious or immediately life-threatening disease when there are no standard treatment options available or treatment options have been exhausted. We are committed to providing pre-approval access, while maintaining our primary focus on moving investigational therapies through clinical trials and ultimately toward regulatory approvals.

Blueprint’s Managed Access Programs are overseen by the Managed Access Strategy and Governance Steering Committee, which consists of senior leaders across medical affairs, corporate affairs, supply chain, global patient affairs, legal, and others.

When we initiated our first early access program for AYVAKIT in 2018, we established criteria for considering requests for early access based on principles of transparency and equity. We continue to provide global pre-approval access to our investigational medicines, with more than 1,000 cumulative patients receiving therapy, including patients in countries where we do not have operations, and in developing countries.

Read more about our Early Access Policy.

Clinical trial travel support program

We know that clinical trials are often the last and only option for patients with advanced cancer, and ensuring trial access is an important component of equitable care.

To make our clinical trials accessible to patients regardless of their financial situation and remove barriers to participation, we have put in place a clinical trial travel support program. Through this program, we support travel to clinical trial sites for study visits by providing reimbursement of appropriate travel, accommodation, and meals for the patient and a caregiver. To make sure we best meet the needs of trial participants we have consulted patient advocacy organizations, patients, and our clinical trial sites in creating and maintaining this program.

Dr. Nicole Rochester, “Patients First” panel moderator
PATIENT ASSISTANCE

To help patients residing in the U.S. access our commercially available medicines, we created YourBlueprint, a comprehensive patient support program tailored to the needs of patients and caregivers. YourBlueprint is designed to help patients start and stay on therapy while minimizing out-of-pocket costs. The program provides resources across the treatment journey, helping patients access treatment rapidly once prescribed, assisting with financial needs, supporting patients once treatment has begun, and ensuring continued access to therapy.

YourBlueprint programs

- **Co-pay assistance** for commercially-insured patients that can reduce patient costs to as little as $0
- **Patient Assistance Program** to arrange free medicine for eligible patients who have inadequate or no insurance coverage
- **Temporary treatment** to help address delays in insurance coverage
- **Dose exchange** to offer no-cost supply to eligible patients in the event of a dose modification
- **Dedicated case manager support** navigating coverage and access issues as well as providing educational information

All U.S. commercial employees received updated training in 2022 on the YourBlueprint Patient Support Program.

Jill F., living with lung cancer
Patient Experience

Patients are at the center of everything we do. At Blueprint, we believe we have the opportunity and responsibility to change what a diagnosis of cancer or a blood disorder will mean for patients, from a diagnosis that is devastating and scary to one with treatment options that allow patients to maintain their health and their quality of life, and live longer.

PATIENT EDUCATION AND SUPPORT

We know cancer and blood disorders like systemic mastocytosis can be relentless foes. At Blueprint, we do more than deliver innovative treatments. We strive to be partners to the patient communities we serve by improving patient outcomes through innovative development, data generation, and education and support.

To address the needs of patients, we are providing a range of tools and resources, including our ItsSMthing and SuspectSM programs, to empower and inform patients and healthcare providers with information on the signs and symptoms of SM as well as diagnostic tools. Moreover, we have worked closely with commercial and academic laboratories in the U.S. to help them understand biomarker testing needs. In 2022, we continued our sponsored testing program with Labcorp to provide no-charge KIT D816V testing to eligible patients.

TOUCHSTONE SURVEY

In 2022, results from the TouchStone SM Patient and Physician surveys were published in the peer-reviewed journal Cancer. The TouchStone SM Patient Survey is the first real-world study to capture patient perspectives on the holistic impact of SM considering quality of life, symptom burden, pain, daily functioning, use of medications, healthcare services by specialists, and work status. The survey showed that SM symptoms have a profound impact on patients’ lives.

When compared to prior research on colorectal and lung cancer patients, TouchStone participants reported worse physical functioning and mental health. In addition, the TouchStone SM Physician study suggests that there is a gap in provider knowledge regarding the challenge of diagnosing SM.

Following the publication of our U.S. TouchStone survey data, we have expanded the study into Europe, where it is currently underway in five European Union countries as well as Switzerland and the UK.

PATIENT COUNCIL

We have continued to grow our Patient Council program, which involves standing advisory councils comprising patients living with SM, lung, thyroid, breast, endometrial, and ovarian cancer, to advise our cross-functional teams on program strategy, clinical trial design, and education and support initiatives. More than 40 individuals from diverse backgrounds (diagnosis, geography, age, race, stage of disease, etc.) are now participating on these councils, giving feedback on clinical trial recruitment materials, generic drug naming, patient education materials, clinical trial study design, understanding the patient journey, and more. In 2022 we focused specifically on hearing from patients of color and understanding how our words and actions can have an impact. We will continue to increase our efforts in operating as a thoughtful, equitable and allied company when working with and for diverse patients.

This structured insight-sharing program is combined with frequent informal patient storytelling events, which enable our employees to hear directly from patients and caregivers living with the diseases we are seeking to address.
Drug Quality and Safety

QUALITY PROGRAM

Our Global Quality Management System (QMS) lays the framework and expectations for maintaining the highest standard of product quality and data integrity. The Blueprint Global Quality Manual, part of our QMS, applies to good practice (GxP) activities conducted throughout the product life cycle. We adhere to guidelines set forth by the International Council on Harmonization (ICH) and the health authorities of countries where Blueprint conducts its operations or where our products are marketed. This includes, but is not limited to, the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Oversight

The Head of Quality is responsible for the design, implementation, functioning, and oversight of the Global QMS at Blueprint. In the event issues arise, Blueprint Quality has processes in place to escalate significant quality compliance and quality issues to the Executive Recall Committee.

The effectiveness of the Global QMS is assessed in three ways: internal audits, authority inspections, and management review. Regularly scheduled Quality Management Reviews are conducted to assess internal and external quality events and trends. The Material Review Board (MRB), consisting of leaders from Quality, Regulatory Affairs, and Technical Operations, is required to meet and assess the fate of any non-conforming product on a case-by-case basis.

Blueprint's Global Quality Management System:

- Ensures that Blueprint’s products and services satisfy the expectations of patients and customers, and meet other public health needs in compliance with applicable laws and regulations.
- Encompasses and incorporates both Blueprint Corporate and Regional Quality Systems compliance elements and requirements.
- Is risk-based and includes quality compliance standards specific to the Blueprint product portfolio.
- Is intended to constantly evolve and improve to satisfy global GxP compliance requirements and to support the needs of Blueprint's business functions and operations.

Training

Our training program is designed to deliver the full scope of required training material to Quality and Research employees in order to support their function and role. At a minimum, Quality Leadership reviews and assesses the training framework annually to adjust curricula and requirements as needed.

GxP vendor management and audit program

Blueprint’s Vendor Management Program and related standard operating procedures (SOPs) ensure that GxP vendors are chosen for their ability to provide products and services according to the company’s needs while adhering to applicable regulations. As part of the selection process, all vendors are qualified by the Quality Unit for the products and services they provide and are held to the terms of contract per a Quality Agreement where appropriate. Once a vendor is onboarded, we conduct routine monitoring through our audit program.
The Blueprint audit program includes external vendor audits, investigator site audits during clinical studies, and internal self-assessments of our quality processes. We apply a risk-based approach in determining the frequency of audits and the implementation of Quality Agreements with vendors. Blueprint also utilizes external quality consultant agencies and private consultants for our auditing purposes. Audits are tracked through Quality Management System tools.

ADVERSE EVENTS AND PRODUCT RECALLS

In accordance with Good Pharmacovigilance Practices (GVP), we report adverse events, quality events, and product complaints when we become aware of them. The Blueprint Quality Event Process is used to investigate impact and implement immediate corrective actions, in addition to approving additional corrective and preventive actions (CAPA) for remediation of an event.

We maintain robust SOPs that follow GxP and applicable regulations in the event of a commercial product recall. Our Executive Recall Committee and Recall Execution Team assess the potential risk to patients, evaluate situations that may affect safety or quality, and develop a recall strategy. In 2022 we had no product recalls.

Refer to our Code of Conduct for more information on Adverse Event and Product Complaint Policy and reporting channels.

PRODUCT INTEGRITY

We are committed to complying with the Drug Supply Chain Security Act (DSCSA) to safeguard our supply chain against suspect, illegitimate, and counterfeit products. Our standard operating procedures include requirements around product tracing, product identifiers, authorized trading partners, and verification.

We have implemented compliant serialization practices into our supply chain for commercial products such that every unit has a unique identifier, enabling the relevant parts of product supply chain to be halted if a transaction takes place involving a falsified product.

We are committed to ensuring our supply chain partners have the relevant qualifications and validated track-and-trace systems to look up and verify serial numbers. We also require our partners to maintain requisite training and policies to enable comprehensive reporting.

Vendor Management

We partner with leading industry organizations primarily in North America and Europe to develop and manufacture our therapies consistent with Good Manufacturing Practice regulations and guidelines. Our Code of Business Conduct and Ethics provides general guidelines for how we conduct business with the highest standards of ethics, and our Procurement Policy outlines awarding business and contracting with vendors, issuing purchase orders, and maintaining ethical standards and fair-trade practices.

While working with outsourced Contract Development and Manufacturing Organizations that offer a broad range of technologies and capabilities, we maintain a robust program for supplier selection and qualification. This process enables us to select partners that align with our cultural values; promote equity, diversity, and inclusion; and hold themselves to the highest ethical, social, and environmental standards.
Employees and Culture

At Blueprint, we are committed to creating an environment where all employees, also known as the Blue Crew, feel a sense of belonging and are empowered to thrive. We are intentional in how we build and nurture our culture, maintaining transparency and fostering trust. We believe equitable practices, both internally and externally, strengthen our inclusive environment, thus sustaining diversity.
OUR CULTURE DEFINED

Here at Blueprint, our culture is grounded in three core beliefs:

• **We’re better together.** Connection and collaboration across disciplines is critical to accomplish our mission. We create space for diverse perspectives and backgrounds, which makes us stronger because we are more creative and, ultimately, more successful when multiple voices are part of the conversation.

• **We live courage and integrity.** We do hard things, and we don’t turn away from a challenge when it’s an opportunity. We take calculated risks, push boundaries, and defy obstacles. This is part of our DNA: to be lifelong learners. We do the right thing and set the bar high. We own our decisions and admit our mistakes.

• **We are human.** In order to remain focused on what matters most — extending and improving the lives of patients — we believe in showing up as we are while embracing our imperfections. We empower ourselves to weigh risk-benefit, make critical decisions quickly, and pave our own path. We prioritize health and well-being because we can’t go the distance unless we take care of ourselves and each other.

“Awe believe everyone should have the opportunity to thrive, and in today’s world, we recognize that not everyone is given an equal chance. We are breaking down those barriers to make a real difference and are proud of our track record but relentless in our pursuit.”

— DEBBIE BUMPUS, CHIEF PEOPLE OFFICER

Awards and recognition

We were honored to be recognized for our equity, diversity, and inclusion (ED&I) work, compensation and benefits offerings, and more in 2022.

Blueprint was named one of the Best Places to Work in 2022 in Massachusetts by the *Boston Globe*.

In addition, Blueprint was ranked third for executive gender diversity and ninth for Board gender diversity among the 75 largest companies in Massachusetts in *Breaking Through to the Top*, a 2023 gender diversity study conducted by the Eos Foundation.
Equity, Diversity, and Inclusion

STRATEGY AND APPROACH

Equity, diversity, and inclusion (ED&I) are a part of our DNA and is embedded in Blueprint’s core values. At Blueprint, we aspire to become a biotech leader in practicing equity, sustaining diversity, and strengthening inclusion, revolutionizing the way organizations ingrain ED&I into business structures and workplace culture. Alongside progressing meaningful ED&I initiatives that serve to elevate marginalized populations, we continually humble ourselves to the things we do not yet know and the work yet to be done.

Blueprint’s ED&I focus areas

To cultivate change within our organization and beyond, we have structured our ED&I strategy into three focus areas: community, business impact, and talent.

These focus areas guide our strategic thinking, decision-making, and outcomes. Within each of these focus areas, we prioritize changing the ways in which we function rather than achieving endpoints. This enables us to create feedback loops that continue to cultivate impact into the future. Over the course of 2022, we expanded our partnerships and programs in support of marginalized employee populations and community organizations.

STRUCTURE OF ED&I EFFORTS

In 2022, a full-time, dedicated ED&I role was created to manage our global ED&I strategy, oversee our ED&I Committee, and serve as an adviser to leaders throughout the company. Our ED&I strategy is overseen by our Executive Team and the Board, along with other human capital management initiatives.

The Equity, Diversity, and Inclusion Committee

The ED&I Committee comprises around 60 members — approximately 10% of our employee population — who are internal champions representing various functional areas and leadership levels, including members of the Executive Team. This group serves to ideate and enact ED&I initiatives across the organization, which in turn influences and evolves our culture and business practice. We maintain monthly full committee and subcommittee meetings as spaces for learning, community, ideation, and initiatives progress.

In 2022, we continued to offer unconscious bias training to all employees and expanded offerings to include educational sessions on intersectionality, microaggressions, allyship, disability etiquette, and environmental racism.

Community-building partnerships

As part of our efforts to build ED&I coalitions and create awareness around disparities, we partner with several organizations nationally and globally. An example includes Work Without Limits (WWL), a network of employers, educational institutions, employment service providers, and state and federal agencies dedicated to increasing the employment of persons with disabilities. Since 2021, we have sponsored WWL’s mission and partnered to host disability etiquette trainings for employees.
2022 HIGHLIGHTS

- Hosted employee focus groups including BIPOC,* white, LGBTQIA+,** international, and customer-facing groups. The learnings from these focus groups were utilized to inform and enhance our ED&I strategy.
- Continued quarterly ED&I Circles, providing safe spaces for employees to find community in light of world events, and to educate on critical topics often excluded in corporate conversations.
- Supported Young Black Pharma (YBP), a professional organization dedicated to developing and creating community spaces for Black biotech professionals.
- Developed a Human Rights Statement to demonstrate our respect for human rights.

- Increased representation of BIPOC individuals across the company.
- Participated in the Bioscience Investor and Inclusion Group (BIIG), a collaborative effort to alleviate systemic inequities in the biotech industry.

Read more about how our ED&I efforts are integrated into how we make decisions as a company in the Diversity in Clinical Trials, Community Giving, and Employee Experience sections of this report.

* Black, Indigenous, and People of Color
** Lesbian, Gay, Bisexual, Transgender, Queer, Intersex, and Asexual

Data is reported as of December 31, 2022. Board data is reported as of January 2023. Underrepresented populations defined as those who self-reported as Black or African American, Hispanic or Latinx, Native American, Alaska Native or Pacific Islander, LGBTQ+, or who identified as two or more races.
Employee Experience

TALENT RECRUITMENT

Creating a workforce of best-in-class scientists, clinicians, business and technical experts, managers, and executive leaders requires a foundation of diverse and representative people who are thoughtful, driven, and hold technical expertise. To build a strong recruitment and development program, we have established a number of opportunities to attract and retain top-tier talent at all levels of the organization, including internships, fellowships, and postdoctoral programs.

In addition, we have created fellowship programs across the organization for high-potential early career business professionals, and we participate in external talent development initiatives such as MassBioEd’s Apprenticeship Program.

Early career development

We supported approximately 100 people in early career development programs in 2022. We believe we work best when we work together, and this includes taking advantage of mentoring opportunities at all levels of the organization. We maintain several mentorship programs, from high school and college internships all the way to fellowships and apprenticeships. Through these offerings, our number of interns has grown by 34% in the past year.

ED&I lens in recruiting and retention

We remain intentional in our goal to attract and retain diverse top-tier talent by routinely monitoring disparities within our organization and shifting our strategy accordingly. In 2022, we addressed gaps by:

- Utilizing an artificial intelligence tool to address biases in job description language
- Expanding partnerships with organizations to increase marginalized representation in the biotech industry, including the American Chemical Society (ACS) Project SEED and Scholar Programs, Life Sciences Cares OnRamp, Healthcare Businesswomen’s Association, and OUTbio
- Sponsoring organizations that elevate talent from marginalized groups with spaces for community and networking

LEARNING AND DEVELOPMENT

We are lifetime knowledge seekers, nurturing a culture of learning and an accelerated pace of talent development. At Blueprint, access to learning and professional development is available to all who pursue it. With multiple opportunities that promote a non-linear approach to continued growth and not bound by the confines of a calendar, program, or role, employees are empowered to drive their own development. After all, employees aren’t just hired for what they can do on day one, but also for what we believe they will do as they learn and grow at Blueprint.

We foster this commitment to growth through broad roles with an expansive responsibility set, experiential leadership development, and skill- and competency-building programs.

The Blue University, our e-learning training center, provides training and learning resources to all employees. In 2022 we launched four professional development workshops with over 70 participants, on topics including how to tell a clear and technical story and how to design and facilitate hybrid meetings. With numerous and varied offerings, employees attended an average of 57 hours of learning and development opportunities per person. This high commitment to training demonstrates both our employees’ excitement for development opportunities and the true support that managers show for participation in these programs.
Developing our employees into capable and confident leaders is important to us. We offer several resources and programs, including:

- **Mentor Program**: Pairs employees across the business and uses knowledge sharing to accelerate growth and development; foster cross-functional relationships; and strengthen our teaching, learning, and networking skills. All employees are welcome to participate as a mentor or mentee, and in 2022, we had over 120 participants.

- **Blueprint Medicines Organizational Leadership Development (BOLD)**: Internally developed program to teach leadership skills to all people managers.

- **Manager Onboarding Program**: Better equips people managers to integrate into Blueprint and effectively lead their teams. Around 30 people managers attended the session when it rolled out in early 2023. Our comprehensive Manager Handbook provides a reference guide on expectations and responsibilities.

- **Senior Leadership Circle**: A community of senior-level department leaders that come together to learn from each other and engage with executives on enterprise strategy.

- **From Laboratory to Leadership Program**: Hones the skills and knowledge of first-time and developing managers, taking them from competent technical managers to capable business leaders. Two employees were selected to participate in 2022.

Average total number of learning hours per employee in 2022: 57
Developing underrepresented leaders
We acknowledge our responsibility to not only hire diverse and representative talent but also to ensure those of marginalized identities are equipped with knowledge and resources to thrive within our organization and in the broader industry. Additionally, we recognize the diversity disparities in Blueprint’s leadership and across the biotech industry. To address these gaps, Blueprint offers programs and opportunities that elevate marginalized individuals and provide tools to help them develop and transition into positions of leadership, including the Leadership EDGE program and the We Rise Together program.

The Leadership EDGE for Women program series develops emerging leaders by incorporating proven and tested curriculum, shared learning and development, application, and networking. We sponsored two employees in 2022.

We Rise Together is a leadership development program designed to increase the representation of historically marginalized talent populations (BIPOC, women, LGBTQIA+, and individuals with disabilities) at the Associate Director and VP levels. Employees are paired with C-suite executives for training and mentoring.

ENGAGEMENT AND FEEDBACK
At Blueprint, we have designed a rich employee experience that is responsive to continuous feedback and insights.

Engagement and enablement survey
We routinely seek out and act upon employee feedback to optimize the employee experience, including through our annual Engagement and Enablement Survey. In 2022, 94% of our global workforce completed the survey, revealing:

- 93% are proud to work at Blueprint
- 84% are excited to be a part of our future
- 95% know how their role contributes to our goals
- 89% believe the company’s commitment to equity, diversity, and inclusion is genuine
- 97% feel they have a good understanding of our core values

We evaluate results from the survey annually to determine strategic targets as an organization and by department.
Retention
We take a thoughtful approach to developing and retaining talent, which includes opportunities for growth, supporting work environment and schedule flexibility, and celebrating employees with a robust rewards and recognition program. As a result, throughout our history as a company we have achieved a voluntary turnover rate that is below the 2022 industry average.*

Feedback and performance reviews
We pride ourselves on our feedback culture. While we encourage open communication year-round, twice a year we seek out 360 degree feedback from peers, stakeholders, leaders, and direct reports to understand where and how we can make an impact for each employee. As part of this process, employees create a development plan in our performance management system to lay out career aspirations and discuss with managers.

Bias Interrupter program
In 2022, the Bias Interrupter program was launched to increase equity in Blueprint’s end-of-year performance review cycle. Senior leaders across the organization were educated on how to disrupt biases via scenario-based training. These leaders were then paired with a department in which they do not sit and have no affiliation to mitigate conflicts of interest. The program successfully led to increased dialogue on how employees should be assessed and provided opportunities to thrive.

BLUE CREW COMMUNITIES
We maintain four Blue Crew Communities, analogous to Employee Resource Groups, that enhance the culture of our organization and give employees an opportunity to connect on a more personal level.

• Core Values Team: Established to help the company recognize and celebrate our core values together.
• ED&I Committee: Embeds equity into business practices to nurture a culture of belonging and execute on our responsibility to our patients and community, thus sustaining our diverse and representative talent.
• Green Team: Empowers Blueprint in our journey to become a more environmentally friendly and sustainable company.
• Fun Team: Enhances the Blueprint culture by organizing fun and engaging activities for employees.

*Source: Radford Survey.
**BENEFITS**
At Blueprint, our Total Rewards program and philosophy is centered on comprehensive and equitable benefits, rewards and recognition of employees who live our values, and fair compensation and equity. We encourage employees to balance work and life through healthcare, financial security, and overall wellness.

Our Total Rewards program prioritizes choice, flexibility, and inclusion, enabling employees to access benefits that work well for themselves and their families. These benefits include:

- Competitive short-term and long-term incentive compensation and employee stock purchase plan—all employees are eligible for equity awards
- Comprehensive medical, dental, and vision plans
- Retirement savings program with company match
- 12-week family leave at 100% pay for qualifying reasons, including parental leave or caregiver leave
- Career, lifestyle, and productivity coaching
- Two weeklong company shutdowns for employee well-being
- Perks such as commuter benefits and premium access to Modern Health

In 2022, we launched the Lifestyle Spending Account (LSA) program to address the diverse needs of employees that traditional benefit plans may not cover, promoting a more equitable employee experience. The LSA program can be used for fitness, self-care, meditation, meals and nutrition, pet care, and home cleaning and repair services.

We also added ESG-focused fund offerings to our 401(k) program in 2022.

**Rewards and recognition**
We believe people work best when their efforts are recognized by their colleagues. Therefore, we created a program to reward and recognize individuals who deliver exceptional business results through strong performance, exhibit behaviors that reinforce our commitment to our Core Values and lead with integrity, and demonstrate long-term commitment to Blueprint. We use a platform where employees can send recognition to co-workers for a job well done, and we have established three company-wide awards given to employees or teams annually.

**Compensation program**
Fair and equitable pay is critical to retaining valuable talent in our competitive industry. Our compensation program aims to attract, retain, and motivate our employees. We strive to ensure pay programs align with and enable achievement of business goals and core values, and we differentiate pay based on performance.

**Community Giving**
We believe Blueprint has a responsibility to improve the communities in which we work and live. We offer a variety of programs and initiatives for employees to engage with, including, but not limited to:

- Corporate match program supporting employee donations to nonprofit organizations advancing social justice and humanitarian aid
- Company charitable contributions to nonprofit organizations focused on health and economic equity
- Employee volunteer opportunities, including environmental clean-ups and other community projects
- Donation drives to collect items for populations in need via collaborations with Catie's Closet, a nonprofit organization that transforms unused school areas into “stores” for free and discreet shopping; and Prison Book Program, a nonprofit organization that supports the rehabilitation of incarcerated individuals
- Opportunity to participate as a “big” via our partnership with Big Brothers Big Sisters, a nonprofit organization dedicated to helping children realize their potential
Employee Health and Safety

We are committed to protecting the health, well-being, and safety of our employees. We have robust systems in place aligned with federal, state, and local regulations and managed by our facilities team under the oversight of our Chief Financial Officer.

All employees receive new hire safety training that includes general safety, fire safety, emergency evacuation procedures, exposures and medical emergencies, and other topics consistent with regulation and standard practice. In addition, employees working in our laboratories receive annual trainings on potential emergency situations and procedures, including chemical spills and exposures.

2022 community giving metrics

$105,000  
Company charitable contribution

15  
Total number of organizations supported

$18,000  
of employee donations matched through our corporate match program

Employee Health and Safety metrics

6.25%  
Total OSHA recordable incident rate (Cambridge locations)

402  
Employee safety training hours

A Case Study of Community Impact

Prison Book Program

It has been extensively documented that systemic racism exists in the incarceration system. Black individuals represent 13% of the U.S. population, but disproportionately account for 40% of the incarcerated population.*

Access to books plays a huge role in rehabilitation. Prison literacy programs have been shown to improve inmate behavior and lead to lower recidivism rates. Allowing prisoners access to books provides low-cost educational alternatives in addition to rehabilitative benefits.

In January 2022, we collected over 2,000 books for Prison Book Program. Over 1,729 were eligible for the program, and the rest were donated to More Than Words, a local youth-run nonprofit bookstore.

*Source: Prison Policy
Environmental Sustainability

Blueprint is devoted to improving the health of patients through innovative science, and we believe a part of this commitment includes a responsibility to care for our environment. As a global company, we are committed to limiting our impact on the environment and working with Blueprint employees to improve awareness and action on sustainability initiatives. In 2022, we developed an Environmental Statement to guide the company in our strategy and action.
COMMITMENT TO THE ENVIRONMENT

At Blueprint Medicines, we believe human health is inextricably linked with our environment, and responsible environmental stewardship is an important part of our company’s mission to help patients live better lives. Accordingly, we are committed to working with all of our stakeholders to understand and minimize our impact on the environment. In 2022, we published an Environmental Statement confirming our commitment to good environmental stewardship.

EMPLOYEE EDUCATION INITIATIVES

Our Green Team frequently sponsors educational activities to raise employee awareness of sustainability topics, including an annual Earth Day celebration, employee challenge activities focused on waste reduction, and a bike clinic.

As a part of a partnership launched in 2021, the Green Team and ED&I Committee co-led an educational seminar on environmental justice with leaders from Alternatives for Community and Education (ACE), a nonprofit dedicated to raising awareness on the intersection of racism, economic inequity, and environmental issues. In 2022, we expanded our educational efforts around environmental justice by hosting a panel event in collaboration with ACE and GreenRoots, another local nonprofit dedicated to environmental justice via collective action.

Sustainable Operations

We are committed to operating our business in a sustainable manner and limiting our environmental impact, and we have initiated a number of programs to advance these interests.

COMMUTER BENEFITS AND TELECOMMUTING

We provide commuter and telecommuting benefits to our employees, including public transportation subsidies, electric vehicle charging stations, and a bike storage and maintenance room in our Cambridge headquarters. In addition, during the COVID-19 pandemic, we implemented a permanent flexible work model to enable telecommuting. All of the conference rooms at our Cambridge headquarters are equipped for seamless virtual meetings, reducing the need for travel and further reducing associated greenhouse gas emissions.

ENERGY-EFFICIENT SYSTEMS

To limit our energy use, we have installed high-efficiency LED lighting with automatic shut-off timers and motion sensors throughout our headquarters. In addition, we have put in place systems such as proximity sensors to improve HVAC system efficiency and to effectively manage energy utilization in our laboratories.

WATER USAGE AND WASTEWATER MANAGEMENT

We use a reverse osmosis water filtration system to provide purified water to our Cambridge headquarters, with reject water diverted for use in non-potable water applications prior to sewer discharge. In addition, we pre-treat laboratory wastewater daily before it is discharged. Scientists receive new hire and annual trainings on wastewater management procedures, including the Chemical Hygiene Plan, which addresses processes to ensure solvents do not spill or leak into the sewer system and processes for collecting and disposing of solvents safely.
In 2022, we diverted 1,100 pounds of plastic from labs away from landfills and incineration.

HAZARDOUS WASTE REDUCTION AND LABORATORY MANAGEMENT

Our hazardous waste program ensures that we comply with all relevant local, state, and federal regulations. We segregate lab waste according to the primary type of hazard (chemical, biological, or radioactive) and follow the appropriate labeling, storage, and disposal procedures. Routine internal inspections are conducted to ensure compliance.

Blueprint is registered as a small quantity generator of hazardous waste with the Massachusetts Department of Environmental Protection and U.S. Environmental Protection Agency (EPA). Even as a small quantity generator, whenever possible, we try to implement strategies to minimize waste and institute environmentally friendly practices, such as ordering only the quantity of substance needed, using the lowest concentration possible of a toxic constituent, avoiding use of cyanides and other highly toxic chemicals, and using environmentally safe thermometers.

In partnership with a third-party vendor, we maintain a recycling program for laboratory materials, such as pipette tip boxes, wafers, lids, media bottles, and conical tub racks. Many of these materials are not accepted by recycling facilities and would otherwise go to a landfill. In 2022, we diverted 1,100 pounds of plastic from labs away from landfills and incineration.

COMPOSTING AND PAPER MANAGEMENT

Beginning in 2019, we initiated a composting program in our Cambridge headquarters, including food waste and the use of compostable utensils, cups, and plates in our cafeteria. Since 2019, these efforts have reduced environmental impact equivalent to avoiding about 290 gallons of gas.

Initiatives to manage paper waste include recycling, electronic contract management and signature collection, and promotion of eco-friendly printing such as default two-sided print settings for office printers and key-card access printing.
We use a reverse osmosis water filtration system to provide purified water to our Cambridge headquarters, with reject water diverted for use in non-potable water applications prior to sewer discharge.
## UNITED NATIONS SUSTAINABLE DEVELOPMENT GOALS (SDGs)

The United Nations Sustainable Development Goals (SDGs) are a collaborative, global effort to achieve a better and more sustainable future for all. Represented by 17 Global Goals and 169 targets, the SDGs address challenges of poverty, inequality, climate change, environmental degradation, peace, and justice. We identified the key areas where we have the greatest influence and impact through our business strategy, products, and services.

<table>
<thead>
<tr>
<th>Goal</th>
<th>Description</th>
<th>Alignment to Blueprint</th>
</tr>
</thead>
<tbody>
<tr>
<td>3. Ensure healthy lives and promote well-being for everyone at all ages</td>
<td>• FDA approval and subsequent commercialization of two medicines, AYVAKIT and GAVRETO&lt;br&gt;• R&amp;D of precision therapy for treatment of cancer and hematologic disease&lt;br&gt;• R&amp;D practices focusing on patient safety, transparency, and equity&lt;br&gt;• Efforts to increase diversity in clinical trials&lt;br&gt;• Early access programs for investigational therapies&lt;br&gt;• “YourBlueprint” patient assistance programs&lt;br&gt;• Patient education, support, and Patient Council program</td>
<td></td>
</tr>
<tr>
<td>4. Ensure inclusive and equitable quality education and promote lifelong learning opportunities for all</td>
<td>• Community sponsorships to nonprofit organizations such as Women of Color in Pharma and OUTbio&lt;br&gt;• Blueprint’s partnership with organizations such as American Chemical Society (ACS), Life Science Cares, and Young Black Pharma (YBP) to promote marginalized and underrepresented groups in the biotech industry&lt;br&gt;• Leadership EDGE for Women program and We Rise Together leadership development program to promote diverse leaders within Blueprint</td>
<td></td>
</tr>
<tr>
<td>10. Reduce inequality within and among countries</td>
<td>• Early access programs for investigational therapies&lt;br&gt;• “YourBlueprint” patient assistance programs&lt;br&gt;• Patient council and patient education programs&lt;br&gt;• ED&amp;I strategy and initiatives</td>
<td></td>
</tr>
</tbody>
</table>
SUSTAINABILITY ACCOUNTING STANDARDS BOARD (SASB)

In developing this report, we aligned our disclosures with Sustainability Accounting Standards Board (SASB) standards — now housed under the International Sustainability Standards Board (ISSB) — related to the biotechnology and pharmaceuticals industry. The standards help ensure that we address the ESG factors most relevant to our business.

<table>
<thead>
<tr>
<th>Topic</th>
<th>Accounting Metric</th>
<th>SASB Code</th>
<th>Response</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Access to Medicines</strong></td>
<td>Description of actions and initiatives to promote access to healthcare products for priority diseases and in priority countries as defined by the Access to Medicine Index</td>
<td>HC-BP-240a.1</td>
<td>Refer to Corporate Responsibility Report, Access to Medicines, and Patient Experience sections.</td>
</tr>
<tr>
<td></td>
<td>List of products on the WHO List of Prequalified Medicinal Products as part of its Prequalification of Medicines Programme (PQP)</td>
<td>HC-BP-240a.2</td>
<td>We do not have any products that qualify for the WHO List of Prequalified Medicinal Products.</td>
</tr>
<tr>
<td><strong>Affordability &amp; Pricing</strong></td>
<td>Number of settlements of Abbreviated New Drug Application (ANDA) litigation that involved payments and/or provisions to delay bringing an authorized generic product to market for a defined time period</td>
<td>HC-BP-240b.1</td>
<td>We believe the price of our medicines reflects their profound benefits in rare, genomically defined patient populations for which they were developed to treat. We're committed to enabling patient access, and we've designed a robust patient support program in the U.S. to help patients start and stay on therapy while minimizing out-of-pocket costs. In addition, we're committed to reinvesting product revenues into research to bring even more treatment advances to patients with cancer and blood diseases. We periodically consider price increases consistent with inflation and our goal to sustain our R&amp;D efforts.</td>
</tr>
<tr>
<td></td>
<td>Percentage change in (1) average list price and (2) average net price across U.S. product portfolio compared to previous year</td>
<td>HC-BP-240b.2</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Percentage change in (1) list price and (2) net price of product with largest increase compared to previous year</td>
<td>HC-BP-240b.3</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Number of fatalities associated with products as reported in the FDA Adverse Event Reporting System</td>
<td>HC-BP-250a.2</td>
<td>This information for our products can be found in the FDA’s Adverse Event Reporting System here.</td>
</tr>
<tr>
<td></td>
<td>Number of recalls issued, total units recalled</td>
<td>HC-BP-250a.3</td>
<td>There were no recalls issued.</td>
</tr>
<tr>
<td></td>
<td>Total amount of product accepted for take-back, reuse, or disposal</td>
<td>HC-BP-250a.4</td>
<td>Amount of product negligible.</td>
</tr>
<tr>
<td></td>
<td>Number of FDA enforcement actions taken in response to violations of current Good Manufacturing Practices (cGMP), by type</td>
<td>HC-BP-250a.5</td>
<td>We have not had any cGMP violations or enforcement actions.</td>
</tr>
<tr>
<td>Topic</td>
<td>Accounting Metric</td>
<td>SASB Code</td>
<td>Response</td>
</tr>
<tr>
<td>-----------------------------------------</td>
<td>-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
<td>-----------</td>
<td>--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------</td>
</tr>
<tr>
<td>Counterfeit Drugs</td>
<td>Description of methods and technologies used to maintain traceability of products throughout the supply chain and prevent counterfeiting</td>
<td>HC-BP-260a.1</td>
<td>We have implemented fully compliant serialization practices into our supply chain for commercial products such that every unit has a unique identifier, enabling the relevant parts of product supply chain to be halted if a transaction takes place involving a falsified product.</td>
</tr>
<tr>
<td></td>
<td>Discussion of process for alerting customers and business partners of potential or known risks associated with counterfeit products</td>
<td>HC-BP-260a.2</td>
<td>We have internal processes in place to ensure risks associated with unsafe products are managed. As of December 31, 2022, no alerts have been received.</td>
</tr>
<tr>
<td></td>
<td>Number of actions that led to raids, seizure, arrests, and/or filing of criminal charges related to counterfeit products</td>
<td>HC-BP-260a.3</td>
<td>None.</td>
</tr>
<tr>
<td>Safety of Clinical Trial Participants</td>
<td>Discussion, by world region, of management process for ensuring quality and patient safety during clinical trials</td>
<td>HC-BP-210a.1</td>
<td>Refer to Corporate Responsibility Report, Safety of Clinical Trials section.</td>
</tr>
<tr>
<td></td>
<td>Number of FDA Sponsor Inspections related to clinical trial management and pharmacovigilance that resulted in (1) Voluntary Action Indicated (VAI) and (2) Official Action Indicated (OAI)</td>
<td>HC-BP-210a.2</td>
<td>No trials were inspected that resulted in classification of VAI/OAI.</td>
</tr>
<tr>
<td></td>
<td>Total amount of monetary losses as a result of legal proceedings associated with clinical trials in developing countries</td>
<td>HC-BP-210a.3</td>
<td>No material losses resulting from legal proceedings.</td>
</tr>
<tr>
<td>Ethical Marketing</td>
<td>Total amount of monetary losses as a result of legal proceedings associated with false marketing claims</td>
<td>HC-BP-270a.1</td>
<td>No material losses resulting from legal proceedings.</td>
</tr>
<tr>
<td></td>
<td>Description of code of ethics governing promotion of off-label use of products</td>
<td>HC-BP-270a.2</td>
<td>Refer to Corporate Responsibility Report, Ethical Marketing section.</td>
</tr>
<tr>
<td>Business Ethics</td>
<td>Total amount of monetary losses as a result of legal proceedings associated with corruption and bribery</td>
<td>HC-BP-510a.1</td>
<td>No material losses resulting from legal proceedings.</td>
</tr>
<tr>
<td></td>
<td>Description of code of ethics governing interactions with healthcare professionals</td>
<td>HC-BP-510a.2</td>
<td>Refer to Corporate Responsibility Report, Business Ethics and Integrity and Ethical Marketing sections.</td>
</tr>
<tr>
<td>Employee Recruitment, Development, and Retention</td>
<td>Discussion of talent recruitment and retention efforts for scientists and research and development personnel</td>
<td>HC-BP-330a.1</td>
<td>Refer to Corporate Responsibility Report, Employees and Culture section.</td>
</tr>
<tr>
<td></td>
<td>(1) Voluntary and (2) involuntary turnover rate for (a) executives/senior managers, (b) midlevel managers, (c) professionals, and (d) all others</td>
<td>HC-BP-330a.2</td>
<td>Refer to Corporate Responsibility Report, Employees and Culture section.</td>
</tr>
</tbody>
</table>
### Activity Metric | SASB Code | Response
---|---|---
Number of Patients Treated | HC-BP-000.A | Nearly 1,200 patients worldwide have been treated with AYVAKIT since its initial commercial launch.

Number of Drugs (1) in Portfolio and (2) in Research and Development (Phases 1-3) | HC-BP-270a.2 | Our portfolio includes 8 precision therapies. This includes 2 approved medicines, which are also being evaluated for additional indications, 4 investigational therapies in Phase 1-3 clinical development for initial indications, and 2 in preclinical development.

### EMPLOYEE DIVERSITY METRICS

<table>
<thead>
<tr>
<th>Global Company Snapshot</th>
<th>2022</th>
<th>2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total employees</td>
<td>615</td>
<td>515</td>
</tr>
<tr>
<td>U.S. employees</td>
<td>563</td>
<td>478</td>
</tr>
</tbody>
</table>

**Global Gender Diversity (%)**
- Female: 56% (2022), 56% (2021)
- Male: 44% (2022), 44% (2021)

**Racial Diversity of U.S. Workforce (%)**
- Native American or Alaska Native or Pacific Islander: 0% (2022), 0% (2021)
- Asian: 24% (2022), 22% (2021)
- Black or African American: 6% (2022), 5% (2021)
- Hispanic or Latinx: 5% (2022), 4% (2021)
- Two or more races: 1% (2022), 1% (2021)
- White: 64% (2022), 68% (2021)

**Executive Team**
- Members: 12 (2022), 12 (2021)
- Female members: 6 (2022), 6 (2021)
- Members from underrepresented populations: 4 (2022), 4 (2021)

**Board of Directors**
- Members: 10 (2022), 10 (2021)
- Female members: 3 (2022), 3 (2021)
- Members from underrepresented populations: 2 (2022), 1 (2021)

*Data is reported as of December 31, 2022. Underrepresented populations are defined as those who self-reported as Black or African American, Hispanic or Latinx, Native American, Alaska Native or Pacific Islander, LGBTQ+, or who identified as two or more races.*
Cautionary Note Regarding Forward-Looking Statements

This Corporate Responsibility Report contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended, without limitation; statements regarding plans, strategies, timelines, and expectations for Blueprint Medicines’ current or future approved drugs and drug candidates; expectations related to the markets for Blueprint Medicines’ current or future approved drugs and drug candidates; the potential benefits of any of Blueprint Medicines’ current or future approved drugs or drug candidates in treating patients; and our financial performance, strategy, goals and anticipated milestones, business plans, and focus. While we believe the forward-looking statements contained in this Corporate Responsibility Report are accurate, these forward-looking statements represent our beliefs only as of the date of this Corporate Responsibility Report, and there are a number of risks and uncertainties that could cause actual events or results to differ materially from those indicated by such forward-looking statements.

Any forward-looking statements in this Corporate Responsibility Report are based on management’s current expectations and beliefs and are subject to a number of risks, uncertainties, and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this Corporate Responsibility Report, including, without limitation, risks and uncertainties related to our ability and plans in continuing to expand a commercial infrastructure, and successfully launching, marketing, and selling current or future approved products; our ability to successfully expand the approved indications for AYVAKIT/AYVAKYT or obtain marketing approval for AYVAKIT/AYVAKYT in additional geographies in the future; the delay of any current or planned clinical trials or the development of our current or future drug candidates; our advancement of multiple early-stage efforts; our ability to successfully demonstrate the safety and efficacy of our drug candidates and gain approval of our drug candidates on a timely basis, if at all; the preclinical and clinical results for our drug candidates, which may not support further development of such drug candidates either as monotherapies or in combination with other agents or may impact the anticipated timing of data or regulatory submissions; actions of regulatory agencies, which may affect the initiation, timing, and progress of clinical trials; our ability to obtain, maintain, and enforce patent and other intellectual property protection for its products or any drug candidates it is developing; our ability to develop and commercialize companion diagnostic tests for its products or any of its current and future drug candidates; our ability to successfully expand our research platform and the costs thereof; and the success of our current and future collaborations, partnerships, or licensing arrangements. These and other risks and uncertainties are described in greater detail in the section entitled “Risk Factors” in our filings with the Securities and Exchange Commission (SEC), including our Corporate Responsibility Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on February 16, 2023, and any other filings that we have made or may make with the SEC in the future. Any forward-looking statements contained in this Corporate Responsibility Report represent our views only as of April 28, 2023, and should not be relied upon as representing its views as of any subsequent date. Except as required by law, we assume no obligation to update or revise these forward-looking statements for any reason, even if new information becomes available in the future.